DAFTAR PUSTAKA

Ajjarapu, S.M. *et al.* (2021) 'Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer', *BMC Pharmacology & Toxicology*, 22, p. 68. Available at: https://doi.org/10.1186/s40360-021-00512-y.

Alamolhodaei, N.S. *et al.* (2017) 'Resveratrol as MDR reversion molecule in breast cancer: An overview', *Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association*, 103, pp. 223–232. Available at: https://doi.org/10.1016/j.fct.2017.03.024.

Ali, S. *et al.* (2016) 'Molecular mechanisms and mode of tamoxifen resistance in breast cancer', *Bioinformation*, 12(3), pp. 135–139. Available at: https://doi.org/10.6026/97320630012135.

Andrikopoulou, A. *et al.* (2022) '"The emerging role of capivasertib in breast cancer"', *The Breast : Official Journal of the European Society of Mastology*, 63, pp. 157–167. Available at: https://doi.org/10.1016/j.breast.2022.03.018.

Arwansyah & Hasrianti. (2014) 'Simulasi Molecular Docking Senyawa Kurkumin dan Analognya Sebagai Selective Androgen Receptor Modulators (SARMs) Pada Kanker Prostat', *Jurnal Dinamika,* 5 (2), pp. 60–75.

Astuty, P. and Komari, N. (2022) 'Kajian Molecular Docking Senyawa Karwinaphthol B dari Tanaman Bawang Dayak (Eleutherine palmifolia (L.) Merr) sebagai Inhibitor Enzim Glukokinase', *Jurnal Natural Scientiae*, 2(1). Available at: https://doi.org/10.20527/jns.v2i1.5412.

Barabási, A.-L., Gulbahce, N. and Loscalzo, J. (2011) 'Network Medicine: A Network-based Approach to Human Disease', *Nature reviews. Genetics*, 12(1), pp. 56–68. Available at: https://doi.org/10.1038/nrg2918.

Te Boekhorst, V. and Friedl, P. (2016) 'Plasticity of Cancer Cell Invasion—Mechanisms and Implications for Therapy', in *Advances in Cancer Research*. Elsevier, pp. 209–264. Available at: https://doi.org/10.1016/bs.acr.2016.07.005.

Braicu, C. *et al.* (2019) 'A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer', *Cancers*, 11(10), p. 1618. Available at: https://doi.org/10.3390/cancers11101618.

Brennan, A. *et al.* (2020) 'Selective antagonism of cJun for cancer therapy', *Journal of Experimental & Clinical Cancer Research*, 39(1), p. 184. Available at: https://doi.org/10.1186/s13046-020-01686-9.

Casanova, F. *et al.* (2012) 'Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest', *Journal of Cellular Biochemistry*, 113(8), pp. 2586–2596. Available at: https://doi.org/10.1002/jcb.24134.

Chan, J.Y. *et al.* (2008) 'Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: The roles of caspase-6 and p53', *Cancer Biology & Therapy*, 7(8), pp. 1305–1312. Available at: https://doi.org/10.4161/cbt.7.8.6302.

Chang, M. (2012) 'Tamoxifen Resistance in Breast Cancer', *Biomolecules & Therapeutics*, 20(3), pp. 256–267. Available at: https://doi.org/10.4062/biomolther.2012.20.3.256.

Chopra, I. *et al.* (2022) *Structural insights into conformational stability of ESR1 and structure base screening of new potent inhibitor for the treatment of Breast Cancer*. preprint. In Review. Available at: https://doi.org/10.21203/rs.3.rs-1413803/v1.

Cocetta, V. *et al.* (2021) 'Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives', *International Journal of Molecular Sciences*, 22(4), p. 2049. Available at: https://doi.org/10.3390/ijms22042049.

Dewi, P.P.P., 2019. Molecular Docking Terpinen-4-ol pada Protein IKK sebagai Antiinflamasi pada Aterosklerosis secara In Silico. *Jurnal Kimia (Journal Of Chemistry)* 13 (2), JULI 2019 : 221-228. doi :10.24843/JFU.2019.v08.i01.p07

Dustin, D., Gu, G. and Fuqua, S.A. (2019) 'ESR1 Mutations in Breast Cancer', *Cancer*, 125(21), pp. 3714–3728. Available at: https://doi.org/10.1002/cncr.32345.

Garces de los Fayos Alonso, I. *et al.* (2018) 'The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas', *Cancers*, 10(4), p. 93. Available at: https://doi.org/10.3390/cancers10040093.

Goldberg, D.M.; Yan, J.; Ng, E.; Diamandis, E.P.; Karumanchiri, A.; Soleas, G.; Waterhouse, A.L (1995) 'A Global Survey of Trans- Resveratrol Concentrations in Commercial Wines', *Enol Vitic*, 46, pp. 159–165.

Gucalp, A. *et al.* (2011) 'Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer', *Clinical breast cancer*, 11(5), pp. 306–311. Available at: https://doi.org/10.1016/j.clbc.2011.03.021.

Han, G.H. *et al.* (2019) 'Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer', *BMC Cancer*, 19(1), p. 1202. Available at: https://doi.org/10.1186/s12885-019-6406-6.

Harikumar, K.B. *et al.* (2010) 'Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer', *International journal of cancer. Journal international du cancer*, 127(2), pp. 257–268. Available at: https://doi.org/10.1002/ijc.25041.

Hermawan, A., Putri, H. and Ikawati, M. (2020) 'Bioinformatic analysis reveals the molecular targets of tangeretin in overcoming the resistance of breast cancer to tamoxifen', *Gene Reports*, 21, p. 100884. Available at: https://doi.org/10.1016/j.genrep.2020.100884.

Hinz, N. and Jücker, M. (2019) 'Distinct functions of AKT isoforms in breast cancer: a comprehensive review', *Cell Communication and Signaling : CCS*, 17. Available at: https://doi.org/10.1186/s12964-019-0450-3.

Hu, C. *et al.* (2019) 'Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling', *Cell Biology and Toxicology*, 35(5), pp. 445–456. Available at: https://doi.org/10.1007/s10565-019-09471-x.

Hurtado, D.X. *et al.* (2020) 'Prostaglandins Isolated from the Octocoral Plexaura homomalla: In Silico and In Vitro Studies Against Different Enzymes of Cancer', *Marine Drugs*, 18(3), p. 141. Available at: https://doi.org/10.3390/md18030141.

Ikawati, Z., 2018. *Farmakologi Molekuler: Target Aksi Obat dan Mekanisme Molekulernya.* Ugm Press.

Irwin, M.E. *et al.* (2011) 'Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib', *Journal of Cellular Physiology*, 226(9), pp. 2316–2328. Available at: https://doi.org/10.1002/jcp.22570.

Iskandar, I. (2021) *Efek Ekspresi mRNA Gen Prolactin Receptor (Prlr) Dan Signal Transducer And Activator Of Transcription 5 (Stat5) Terhadap Produksi Asi Ibu Menyusui*. doctoral. Universitas Hasanuddin. Available at: http://repository.unhas.ac.id/id/eprint/3262/ (Accessed: 8 March 2023).

Kannaiyan, R. and Mahadevan, D. (2018) 'A comprehensive review of protein kinase inhibitors for cancer therapy', *Expert review of anticancer therapy*, 18(12), pp. 1249–1270. Available at: https://doi.org/10.1080/14737140.2018.1527688.

Kong, D. *et al.* (2022) 'Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas', *International Journal of Nanomedicine*, Volume 17, pp. 1087–1110. Available at: https://doi.org/10.2147/IJN.S346948.

Lee, H., Jeong, A.J. and Ye, S.-K. (2019) 'Highlighted STAT3 as a potential drug target for cancer therapy', *BMB Reports*, 52(7), pp. 415–423. Available at: https://doi.org/10.5483/BMBRep.2019.52.7.152.

Li, K. *et al.* (2020) 'Bioinformatics Approaches for Anti-cancer Drug Discovery', *Current Drug Targets*, 21(1), pp. 3–17. Available at: https://doi.org/10.2174/1389450120666190923162203.

Ma, X. *et al.* (2022) 'Integration of network pharmacology and molecular docking to explore the molecular mechanism of Cordycepin in the treatment of Alzheimer's disease', *Frontiers in Aging Neuroscience*, 14. Available at: https://doi.org/10.3389/fnagi.2022.1058780.

Madden, S.K. *et al.* (2021) 'Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc', *Molecular Cancer*, 20(1), p. 3. Available at: https://doi.org/10.1186/s12943-020-01291-6.

Masoud, G.N. and Li, W. (2015) 'HIF-1α pathway: role, regulation and intervention for cancer therapy', *Acta Pharmaceutica Sinica. B*, 5(5), pp. 378–389. Available at: https://doi.org/10.1016/j.apsb.2015.05.007.

McDade, S.S. and Fischer, M. (2018) 'TP53', in *Reference Module in Biomedical Sciences*. Elsevier, p. B9780128012383650000. Available at: https://doi.org/10.1016/B978-0-12-801238-3.64985-1.

Ozaki, T. and Nakagawara, A. (2011) 'Role of p53 in Cell Death and Human Cancers', *Cancers*, 3(1), p. 994. Available at: https://doi.org/10.3390/cancers3010994.

Pantsar, T., & Poso, A. 2018, 'Binding affinity via docking: fact and fiction', *Molecules*, vol. 23, no. 8, p. 1899.

Pistritto, G. *et al.* (2016) 'Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies', *Aging*, 8(4), pp. 603–619. Available at: https://doi.org/10.18632/aging.100934.

Riggins, R.B. *et al.* (2017) 'Pathways to Tamoxifen Resistance', *Cancer letters*, 256(1), pp. 1–24. Available at: https://doi.org/10.1016/j.canlet.2007.03.016.

Saputri, K.E. *et al.* (2016) 'Docking Molekular Potensi Anti Diabetes Melitus Tipe 2 Turunan Zerumbon Sebagai Inhibitor Aldosa Reduktase Dengan Autodock-

Vina', *Chimica et Natura Acta*, 4(1), p. 16. Available at: https://doi.org/10.24198/cna.v4.n1.10443.

Shanak, S., Bassalat, N., Barghash, A., Kadan, S., Ardah, M., & Zaid, H. 2022, 'Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches', *Evidence-Based Complementary and Alternative Medicine*, vol. 2022

Shi, X.-P. *et al.* (2013) 'Resveratrol Sensitizes Tamoxifen in Antiestrogen-Resistant Breast Cancer Cells with Epithelial-Mesenchymal Transition Features', *International Journal of Molecular Sciences*, 14(8), pp. 15655–15668. Available at: https://doi.org/10.3390/ijms140815655.

Shirai, Y. *et al.* (2021) 'An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor', *Cancers*, 13(11), p. 2813. Available at: https://doi.org/10.3390/cancers13112813.

Tao, Z. *et al.* (2017) 'Microarray bioinformatics in cancer- a review', *Journal of B.U.ON.: official journal of the Balkan Union of Oncology*, 22(4), pp. 838–843.

Vargas, J.E. *et al.* (2015) 'Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer: A Translational In Vitro–In Silico Model', *Oxidative Medicine and Cellular Longevity*, p. 23.

Vinod, B.S. (2015) 'Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis', *Cell Death Discovery*, p. 9.

Yao, J. *et al.* (2020) 'Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer', *Frontiers in Pharmacology*, 11. Available at: https://www.frontiersin.org/articles/10.3389/fphar.2020.592912 (Accessed: 6 January 2023).

Zhang, S. and Yu, D. (2012) 'Targeting Src family kinases in anti-cancer therapies: turning promise into triumph', *Trends in pharmacological sciences*, 33(3), pp. 122–128. Available at: https://doi.org/10.1016/j.tips.2011.11.002.

Zhang, Y. and Wang, X. (2020) 'Targeting the Wnt/β-catenin signaling pathway in cancer', *Journal of Hematology & Oncology*, 13(1), p. 165. Available at: https://doi.org/10.1186/s13045-020-00990-3.

Zubair, Muhammad Sulaiman., Saipul Maulana., & Alwiyah Mukaddas. (2020) 'Penambatan Molekuler dan Simulasi Dinamika Molekuler Senyawa dari Genus Nigella Terhadap Penghambatan Aktivitas Enzim Protease HIV-1', *Jurnal Farmasi Galenika*, 6(1), pp. 132-140.